Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INM 
InMed Pharmaceuticals Inc (INM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: INM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.77% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.08M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) - | Beta 0.28 | 52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 |
52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -168.9% | Operating Margin (TTM) -167.67% |
Management Effectiveness
Return on Assets (TTM) -44.64% | Return on Equity (TTM) -91.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 297344 | Price to Sales(TTM) 0.83 |
Enterprise Value 297344 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 1 | Shares Outstanding 1207190 | Shares Floating 1205387 |
Shares Outstanding 1207190 | Shares Floating 1205387 | ||
Percent Insiders 1.45 | Percent Institutions 10.18 |
Upturn AI SWOT
InMed Pharmaceuticals Inc
Company Overview
History and Background
InMed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing cannabinoid-based therapeutics and delivery systems. Founded to explore the therapeutic potential of cannabinoids, the company has evolved into a research and development firm focused on creating innovative solutions for unmet medical needs.
Core Business Areas
- Drug Development: InMed focuses on the research and development of novel cannabinoid-based therapeutics targeting diseases with high unmet medical needs.
- Biosynthesis: The company works on developing a biosynthesis platform for the manufacturing of cannabinoids, aiming for cost-effective and scalable production.
Leadership and Structure
InMed Pharmaceuticals Inc. has a leadership team comprised of individuals with experience in drug development, biotechnology, and finance. The organizational structure includes research and development, clinical operations, and corporate management teams.
Top Products and Market Share
Key Offerings
- INM-901: INM-901 is an investigational cannabinol (CBN) product developed as a topical formulation for the treatment of epidermolysis bullosa (EB). Market share data is currently unavailable as it's in development. Competitors in EB treatments include Krystal Biotech (KRYS) and Abeona Therapeutics (ABEO).
- CBN API: InMed is developing a pharmaceutical-grade CBN (cannabinol) API through biosynthesis. Market share data is unavailable as it's in development. Competitors in the cannabinoid API market include various producers of pharmaceutical-grade cannabinoids.
Market Dynamics
Industry Overview
The pharmaceutical industry is constantly evolving, driven by new scientific discoveries and unmet medical needs. The cannabinoid-based therapeutics sector is rapidly growing as researchers explore the potential benefits of cannabinoids in treating various diseases.
Positioning
InMed Pharmaceuticals Inc. is positioning itself as a leader in the development of cannabinoid-based therapeutics and cannabinoid production through biosynthesis. Their competitive advantage lies in their CBN product INM-901 for epidermolysis bullosa, and biosynthesis process.
Total Addressable Market (TAM)
The total addressable market for epidermolysis bullosa (EB) treatments is projected to reach hundreds of millions of dollars. The total addressable market for cannabinoid APIs is several billions. InMed is positioning itself to capture a portion of these markets through their drug candidate and their production technology.
Upturn SWOT Analysis
Strengths
- Novel CBN-based therapeutic approach
- Biosynthesis platform for cost-effective cannabinoid production
- Focus on unmet medical needs (epidermolysis bullosa)
- Experienced management team
Weaknesses
- Early stage of development
- Limited financial resources
- Reliance on clinical trial success
- Competition in the cannabinoid market
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with additional cannabinoid therapeutics
- Regulatory approval of INM-901
- Market growth in cannabinoid-based medicines
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in cannabis legislation
Competitors and Market Share
Key Competitors
- KRYS
- ABEO
- GWPH
Competitive Landscape
InMed Pharmaceuticals Inc. faces competition from larger pharmaceutical companies and other biotechnology firms in the cannabinoid space. Their competitive advantage lies in their specific focus on CBN-based therapeutics and biosynthesis capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by research and development progress, preclinical and clinical trial milestones, and financial fundraising activities.
Future Projections: Future growth is dependent on the successful development and commercialization of INM-901 and other pipeline candidates. Analyst estimates vary depending on clinical trial outcomes and market adoption.
Recent Initiatives: Recent initiatives include advancing INM-901 through clinical trials, optimizing the biosynthesis platform for cannabinoid production, and seeking partnerships for development and commercialization.
Summary
InMed Pharmaceuticals is a development-stage biopharmaceutical company focused on cannabinoid-based therapeutics, particularly CBN. It is developing a novel topical product for EB with limited market share at this stage. The company's biosynthesis capabilities provide a unique advantage, but successful clinical trials and regulatory approvals are crucial for future growth. InMed faces the typical risks of a biotech company, including clinical trial failures and funding constraints. Overall, INMD is a high-risk, high-reward investment dependent on future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company press releases
- Analyst reports
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-11-12 | President, CEO & Director Mr. Eric A. Adams B.S. Chem., M.I.B. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://www.inmedpharma.com |
Full time employees 13 | Website https://www.inmedpharma.com | ||
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.